JAK1 and infection: We next tested the JAK1/2 inhibitor ruxolitinib, which acts upstream of STAT1 and is broadly effective at preventing IFN (and another cytokine) signaling, and again observed that JAK1/2 inhibition did not rescue the infection defect associated with p38β knockdown (Fig. S4F).